PARP inhibitor combinations in prostate cancer

Polyadenosine-diphosphate-ribose polymerase (PARP) inhibitors cause deoxyribonucleic acid (DNA) damage that can be lethal to cells with deficient repair mechanisms. A number of PARP inhibitors are being tested as treatments for men with prostate cancer, both as monotherapies and in combinations that...

Descripción completa

Detalles Bibliográficos
Autor principal: Pezaro, Carmel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Challenging Dogma: New Evidence to Guide Practice in Urologic Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081465/
https://www.ncbi.nlm.nih.gov/pubmed/32215055
http://dx.doi.org/10.1177/1758835919897537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081465/
https://www.ncbi.nlm.nih.gov/pubmed/32215055
http://dx.doi.org/10.1177/1758835919897537

Ejemplares similares